Patricia Hirano serves as the Senior Vice President of Regulatory Affairs at Soleno Therapeutics Inc., a company dedicated to developing novel therapeutics for the treatment of rare diseases. With over two decades of experience in the biopharmaceutical industry, Hirano has established herself as a key player in regulatory affairs, particularly in the areas of drug development and approval processes. Her expertise spans multiple therapeutic areas, including endocrinology, neurology, and rare diseases, which aligns perfectly with Soleno's mission to address unmet medical needs. Before joining Soleno Therapeutics, Hirano held significant positions at several leading pharmaceutical companies, where she successfully navigated complex regulatory landscapes to bring new treatments to market. Notably, she played a pivotal role in the approval of several groundbreaking therapies, demonstrating her ability to work effectively with regulatory agencies such as the FDA and EMA. At Soleno, Hirano is responsible for overseeing the company's regulatory strategy, ensuring compliance with all relevant regulations, and guiding the development programs through the necessary approval stages. Her leadership and strategic vision are instrumental in advancing Soleno's pipeline and achieving the company's goal of delivering life-changing treatments to patients with rare diseases. In addition to her professional achievements, Hirano is recognized for her contributions to the field of regulatory affairs through her involvement in various industry associations and her participation in conferences and workshops. Her commitment to mentoring the next generation of regulatory professionals further underscores her dedication to the advancement of the biopharmaceutical industry. Under her guidance, Soleno Therapeutics continues to make significant strides in the development of innovative therapies, cementing its position as a leader in the treatment of rare diseases.